[go: up one dir, main page]

DK1071422T3 - Kombinationer af riluzol og levodopa til behandling af parkinsons sygdom - Google Patents

Kombinationer af riluzol og levodopa til behandling af parkinsons sygdom

Info

Publication number
DK1071422T3
DK1071422T3 DK99915809T DK99915809T DK1071422T3 DK 1071422 T3 DK1071422 T3 DK 1071422T3 DK 99915809 T DK99915809 T DK 99915809T DK 99915809 T DK99915809 T DK 99915809T DK 1071422 T3 DK1071422 T3 DK 1071422T3
Authority
DK
Denmark
Prior art keywords
riluzole
levodopa
disease
parkinson
combinations
Prior art date
Application number
DK99915809T
Other languages
Danish (da)
English (en)
Inventor
Veronique Blanchard-Bregeon
Assunta Imperato
Saliha Moussaoui
Marie-Carmen Obinu
Michel Reibaud
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of DK1071422T3 publication Critical patent/DK1071422T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
DK99915809T 1998-04-24 1999-04-22 Kombinationer af riluzol og levodopa til behandling af parkinsons sygdom DK1071422T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9805153A FR2777781B1 (fr) 1998-04-24 1998-04-24 Associations riluzole et l-dopa pour le traitement de la maladie de parkinson
PCT/FR1999/000953 WO1999055336A1 (fr) 1998-04-24 1999-04-22 Associations de riluzole et de levodopa pour le traitement de la maladie de parkinson

Publications (1)

Publication Number Publication Date
DK1071422T3 true DK1071422T3 (da) 2008-06-16

Family

ID=9525640

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99915809T DK1071422T3 (da) 1998-04-24 1999-04-22 Kombinationer af riluzol og levodopa til behandling af parkinsons sygdom

Country Status (22)

Country Link
US (1) US6387936B1 (el)
EP (1) EP1071422B1 (el)
JP (1) JP2002512963A (el)
KR (1) KR100597170B1 (el)
AT (1) ATE386520T1 (el)
AU (1) AU768069B2 (el)
CA (1) CA2329636C (el)
CY (1) CY1110448T1 (el)
CZ (1) CZ300825B6 (el)
DE (1) DE69938179T2 (el)
DK (1) DK1071422T3 (el)
ES (1) ES2300141T3 (el)
FR (1) FR2777781B1 (el)
HU (1) HU228902B1 (el)
IL (1) IL139164A (el)
NO (1) NO329032B1 (el)
PT (1) PT1071422E (el)
RU (1) RU2225204C2 (el)
SK (1) SK285531B6 (el)
UA (1) UA70319C2 (el)
WO (1) WO1999055336A1 (el)
ZA (1) ZA200005758B (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2786101B1 (fr) * 1998-11-24 2002-07-05 Aventis Laboratoire Utilisation de la nicergoline dans le traitement de la spasticite
DE60041365D1 (de) * 1999-06-04 2009-02-26 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Verwendung von Riluzol zur Behandlung Multipler Sklerose
GB0007193D0 (en) * 2000-03-25 2000-05-17 Univ Manchester Treatment of movrmrnt disorders
US8158149B2 (en) * 2004-05-12 2012-04-17 Chelsea Therapeutics, Inc. Threo-DOPS controlled release formulation
WO2004100929A1 (en) 2003-05-12 2004-11-25 Synergia Pharma, Inc. Threo-dops controlled release formulation
WO2005025561A1 (en) * 2003-09-04 2005-03-24 Synergia Pharma, Inc. Compositions and methods for orthostatic intolerance
WO2005112906A2 (en) * 2004-05-21 2005-12-01 Duke University Method for augmenting the effects of serotonin reuptake inhibitors
SE0401842D0 (sv) * 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
JP5112876B2 (ja) * 2004-11-07 2013-01-09 エフ． ギルフォード ティモシー 還元型グルタチオン経口投与のためのリポソーム処方物
GB0504103D0 (en) * 2005-02-28 2005-04-06 Syngenta Ltd Novel method
US20070148238A1 (en) * 2005-06-23 2007-06-28 Spherics, Inc. Dosage forms for movement disorder treatment
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
HRP20120479T1 (hr) * 2006-06-28 2012-07-31 Chelsea@Therapeutics@Inc Farmaceutski sastavi sa droksidopom
WO2008079404A2 (en) * 2006-12-22 2008-07-03 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
NZ579368A (en) * 2007-03-09 2012-03-30 Chelsea Therapeutics Inc Droxidopa and pharmaceutical composition thereof for the treatment of fibromyalgia
EP2514417A3 (en) * 2007-05-07 2013-01-30 Chelsea Therapeutics, Inc. Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders
US8703809B2 (en) * 2008-06-30 2014-04-22 Novartis Ag Combination products
MX2011004769A (es) * 2008-11-06 2011-11-29 Biotie Therapies Inc Tratamiento de sindrome de pierna sin reposo y alteraciones del sueño.
EP2228054A1 (en) * 2009-03-13 2010-09-15 ITALFARMACO S.p.A. Riluzole aqueous suspensions
WO2012054815A1 (en) 2010-10-22 2012-04-26 Duke University Slow-release formulations of 5-hydroxytryptophan as an adjunct to pro-serotonergic therapies
JP5880913B2 (ja) 2011-05-17 2016-03-09 三郎 佐古田 パーキンソン病の体幹症状（姿勢反射異常）の治療剤
WO2014172372A1 (en) 2013-04-15 2014-10-23 Northwestern University Treatment for dopaminergic disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
RU2057529C1 (ru) * 1994-05-30 1996-04-10 Алексей Михайлович Коршунов Способ лечения синдрома паркинсонизма

Also Published As

Publication number Publication date
IL139164A0 (en) 2001-11-25
AU3425599A (en) 1999-11-16
ATE386520T1 (de) 2008-03-15
WO1999055336A1 (fr) 1999-11-04
CZ300825B6 (cs) 2009-08-19
RU2225204C2 (ru) 2004-03-10
CY1110448T1 (el) 2015-04-29
SK15882000A3 (sk) 2001-04-09
NO329032B1 (no) 2010-08-02
IL139164A (en) 2005-12-18
CA2329636A1 (fr) 1999-11-04
DE69938179D1 (de) 2008-04-03
US6387936B1 (en) 2002-05-14
ES2300141T3 (es) 2008-06-01
CZ20003908A3 (cs) 2001-02-14
UA70319C2 (en) 2004-10-15
FR2777781B1 (fr) 2004-04-09
FR2777781A1 (fr) 1999-10-29
SK285531B6 (sk) 2007-03-01
JP2002512963A (ja) 2002-05-08
PT1071422E (pt) 2008-05-05
CA2329636C (fr) 2009-09-08
KR20010042960A (ko) 2001-05-25
AU768069B2 (en) 2003-12-04
EP1071422B1 (fr) 2008-02-20
NO20005290D0 (no) 2000-10-20
HU228902B1 (en) 2013-06-28
DE69938179T2 (de) 2009-02-12
KR100597170B1 (ko) 2006-07-05
NO20005290L (no) 2000-10-20
EP1071422A1 (fr) 2001-01-31
ZA200005758B (en) 2002-01-17
HUP0101645A3 (en) 2002-10-28
HUP0101645A2 (hu) 2001-09-28

Similar Documents

Publication Publication Date Title
DK1071422T3 (da) Kombinationer af riluzol og levodopa til behandling af parkinsons sygdom
GB0108592D0 (en) Therapeutic agents
DK1303272T3 (da) Benzothiazolderivater til behandling af Alzheimers sygdom og Parkinsons sygdom
BG106450A (en) Use of retigabin for treating neuropathic pain
ATE346039T1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
GB0225475D0 (en) Therapeutic agents
YU401A (sh) Sredstva sa antidepresivnim dejstvom
DK0687177T3 (da) Anvendelse af lamotrigin ved fremstilling af lægemidler til behandling af AIDS-relaterede nervesygdomme
DE69832695D1 (de) Verwendung von r-enantiomeren nichtsteroidaler entzündungshemmer zur vorbeugung der alzheimerschen krankheit
IS5951A (is) 5HT1 mótlyf fyrir meðferð gegn þunglyndi
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
PT1434588E (pt) Derivados de ácido [[-(amino-3,4-dioxo-1-ciclobuteno-1- il)amino]alquil] para o tratamento da dor
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
DK0813870T3 (da) Anvendelse af darifenacin til at forstærke kognitive funktioner
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
EA200000816A1 (ru) Применение 2-амино-6-трифторметоксибензотиазола для профилактики или лечения дисфункции мозжечка
ZA9711719B (en) Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis.
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin
NO934690D0 (no) Anvendelse av atipamezole for behandling av menns impotens
SE9501773D0 (sv) New use
AU2003287513A8 (en) Inhibitors of beta-secretase, and their use for the prevention or treatment of alzheimer's disease or mild cognitive impairment
DK1299102T3 (da) Anvendelse af riluzol eller salte deraf til forebyggelse og behandling af adrenoleukodystrofi
BR9711059A (pt) Utiliza-Æo do efaroxan